skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Technology development for Sr-89 production with 100kW medical isotope production system (MIPS-100). Final CRADA Report.

Abstract

No abstract prepared.

Authors:
;
Publication Date:
Research Org.:
Argonne National Lab. (ANL), Argonne, IL (United States)
Sponsoring Org.:
USDOE National Nuclear Security Administration (NNSA)
OSTI Identifier:
967951
Report Number(s):
ANL/NE-C0000401
TRN: US0904527
DOE Contract Number:
DE-AC02-06CH11357
Resource Type:
Technical Report
Country of Publication:
United States
Language:
ENGLISH
Subject:
38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEAR CHEMISTRY; ISOTOPE PRODUCTION; STRONTIUM 89; TECHNOLOGY UTILIZATION

Citation Formats

Ehst, D. A., and Nuclear Engineering Division. Technology development for Sr-89 production with 100kW medical isotope production system (MIPS-100). Final CRADA Report.. United States: N. p., 2009. Web. doi:10.2172/967951.
Ehst, D. A., & Nuclear Engineering Division. Technology development for Sr-89 production with 100kW medical isotope production system (MIPS-100). Final CRADA Report.. United States. doi:10.2172/967951.
Ehst, D. A., and Nuclear Engineering Division. Fri . "Technology development for Sr-89 production with 100kW medical isotope production system (MIPS-100). Final CRADA Report.". United States. doi:10.2172/967951. https://www.osti.gov/servlets/purl/967951.
@article{osti_967951,
title = {Technology development for Sr-89 production with 100kW medical isotope production system (MIPS-100). Final CRADA Report.},
author = {Ehst, D. A. and Nuclear Engineering Division},
abstractNote = {No abstract prepared.},
doi = {10.2172/967951},
journal = {},
number = ,
volume = ,
place = {United States},
year = {Fri Oct 02 00:00:00 EDT 2009},
month = {Fri Oct 02 00:00:00 EDT 2009}
}

Technical Report:

Save / Share:
  • This was a collaborative effort between Lawrence Livermore National Security, LLC as manager and operator of Lawrence Livermore National Laboratory (LLNL) and ISOFLEX USA (ISOFLEX), to 1) develop and test a prototype waste destruction system ("System") using AC plasma torch technology to break down and drastically reduce the volume of Carbon-14 (C-14) contaminated medical laboratory wastes while satisfying all environmental regulations, and 2) develop and demonstrate methods for recovering 99%+ of the carbon including the C-14 allowing for possible re-use as a tagging and labeling tool in the biomedical industry.
  • This was a collaborative effort between the University of California, Lawrence Livermore National Laboratory (LLNL) and Spectra Gases, Inc., to develop new and cheaper sources of Oxgyen-18 (O-18), Carbon-13 (C-13), and Xenon-129 (Xe-129), and to develop new applications of these stable medical isotopes in medicine resulting in a substantial increase in stable isotopes that are important to human health sciences.
  • The Joint Working Group on Drug Dependent Degradation in Military Performance (JWGD MILPERS) program was established by the U.S. Army Medical Research and Development Command (USAMRDC) as a tri-service program charged with developing and testing performance methodologies for evaluating the effects on military performance from medical treatment and pretreatment drugs used to counter chemical warfare agents. Metters Industries, Inc. provided administrative and technical support to the JWGD3 including opening and operating the JWGD3 MILPERS Field office, developing and maintaining program planning documents including budget and resource requirements, initiating and coordinating contract and MIPR documents on program projects, developing and maintainingmore » microprocessor databasing systems for monitoring project and contract reports and program technology transfers, 3 coordinating and providing administrative support for quarterly and special JWGD meetings, and participating in the development of the Performance Information Management System for archiving, retrieving and dissemination of technical and scientific information for the program. RAV; Medical Chemical Defense; Analytical Services; Software Development; JWGD3MILPERF.« less
  • Under this CRADA, Berkeley Lab and the industry partner, General Atomics (GA), have cooperatively developed hadron therapy technologies for commercialization. Specifically, Berkeley Lab and GA jointly developed beam transport systems to bring the extracted protons from the accelerator to the treatment rooms, rotating gantries to aim the treatment beams precisely into patients from any angle, and patient positioners to align the patient accurately relative to the treatment beams. We have also jointly developed a patient treatment delivery system that controls the radiation doses in the patient, and hardware to improve the accelerator performances, including a radio-frequency ion source and itsmore » low-energy beam transport (LEBT) system. This project facilitated the commercialization of the DOE-developed technologies in hadron therapy by the private sector in order to improve the quality of life of the nation.« less